Sucralfate mouthwash useful and safe management option of cancer therapy-induced OM: Study

Written By : Dr. Shravani Dali |Medically Reviewed By : Dr. Kamal Kant Kohli Published On 2024-09-06T20:30:34+05:30 | Updated On 7 Sept 2024 12:33 PM IST

Sucralfate mouthwash useful and safe management option for cancer therapy-induced oral mucositis suggests a study published in the Oral Diseases.

Oral mucositis (OM) is considered one of the most common side effects of patients undergoing cancer therapy. OM prevention plays a crucial role in the effectiveness of cancer treatment and the patient's quality of life. Different preventive treatments have been proposed in clinical trials, however with inconclusive results. A systematic review search was conducted in PubMed, Scopus, Web of Science, and Cochrane Database to answer the PICO question: in cancer patients, do specific topical agents compared to standard treatments or placebo reduce the onset and severity of oral mucositis?

The risk of bias was assessed, and a network meta-analysis was conducted. Results: Of 2913 results, 30 randomized clinical trials were considered suitable for inclusion. A total of 2564 patients were analyzed, of which 1284 belonged to the test group and 1280 belonged to the control group. Natural products were the most used, followed mainly by antimicrobial agents, coating agents, and basic oral care measures. Topical sucralfate resulted in the most powerful intervention for the OM prevention (OR = 0.04, 95%C.I. = 0.01–0.25, p-value = 0.001). Due to its cytoprotective action, low cost, ease of administration, and safety, sucralfate could become a potential ally to prevent the onset of OM during cancer therapy.

Reference:

Coppini, M., Caponio, V. C. A., Mauceri, R., Bizzoca, M. E., Laino, L., Lorenzo-Pouso, A. I., Russo, D., Troiano, G., Silva, F. F. V. E., Lo Muzio, L., & Campisi, G. (2024). Efficacy of topical agents in oral mucositis prevention: Systematic review and network meta-analysis. Oral Diseases, 00, 1–19. https://doi.org/10.1111/odi.15046

Sucralfatemouthwashusefulsafemanagementoptioncancertherapy–inducedOMStudy

Source : Oral Diseases

Dr. Shravani Dali

Dr. Shravani Dali has completed her BDS from Pravara institute of medical sciences, loni. Following which she extensively worked in the healthcare sector for 2+ years. She has been actively involved in writing blogs in field of health and wellness. Currently she is pursuing her Masters of public health-health administration from Tata institute of social sciences. She can be contacted at editorial@medicaldialogues.in.

Dr. Kamal Kant Kohli

Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: drkohli@medicaldialogues.in. Contact no. 011-43720751